US EditionGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
3 Articles
3 Articles
Hastings Tribune
Bluefield Daily TelegraphGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock…
Release - Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - Channelchek
Research News and Market Data on GYRE May 22, 2025 PDF Version SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters …
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
